Literature DB >> 24046282

Analyses of synovial tissues from arthritic and protected congenic rat strains reveal a new core set of genes associated with disease severity.

Max Brenner1, Teresina Laragione, Pércio S Gulko.   

Abstract

Little is known about the genes regulating disease severity and joint damage in rheumatoid arthritis (RA). In the present study we analyzed the gene expression characteristics of synovial tissues from four different strains congenic for non-MHC loci that develop mild and nonerosive arthritis compared with severe and erosive DA rats. DA.F344(Cia3d), DA.F344(Cia5a), DA.ACI(Cia10), and DA.ACI(Cia25) rats developed mild arthritis compared with DA. We found 685 genes with significantly different expression between congenics and DA, independent of the specific congenic interval, suggesting that these genes represent a new nongenetic core group of mediators of arthritis severity. This core group includes genes not previously implicated or with unclear role in arthritis severity, such as Tnn, Clec4m, and Spond1 among others, increased in DA. The core genes also included Scd1, Selenbp1, and Slc7a10, increased in congenics. Genes implicated in nuclear receptor activity, xenobiotic and lipid metabolism were also increased in the congenics, correlating with protection. Several disease mediators were among the core genes reduced in congenics, including IL-6, IL-17, and Ccl2. Analyses of upstream regulators (genes, pathways, or chemicals) suggested reduced activation of Stat3 and TLR-related genes and chemicals in congenics. Additionally, cigarette smoking was among the upstream regulators activated in DA, while p53 was an upstream regulator activated in congenics. We observed congenic-specific differential expression and detection in each individual strain. In conclusion, this new nongenetically regulated core genes of disease severity or protection in arthritis should provide new insight into critical pathways and potential new environmental risk factor for arthritis.

Entities:  

Keywords:  autoimmunity; environment; erosion; innate; synovitis

Mesh:

Year:  2013        PMID: 24046282      PMCID: PMC3841791          DOI: 10.1152/physiolgenomics.00108.2013

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  49 in total

1.  Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes.

Authors:  C Vingsbo; P Sahlstrand; J G Brun; R Jonsson; T Saxne; R Holmdahl
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium.

Authors:  G S Firestein; F Echeverri; M Yeo; N J Zvaifler; D R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

3.  The non-major histocompatibility complex quantitative trait locus Cia10 contains a major arthritis gene and regulates disease severity, pannus formation, and joint damage.

Authors:  Max Brenner; Hsiang-Chi Meng; Nuriza C Yarlett; Marie M Griffiths; Elaine F Remmers; Ronald L Wilder; Pércio S Gulko
Journal:  Arthritis Rheum       Date:  2005-01

4.  Identification of a new non-major histocompatibility complex genetic locus on chromosome 2 that controls disease severity in collagen-induced arthritis in rats.

Authors:  P S Gulko; Y Kawahito; E F Remmers; V R Reese; J Wang; S V Dracheva; L Ge; R E Longman; J S Shepard; G W Cannon; A D Sawitzke; R L Wilder; M M Griffiths
Journal:  Arthritis Rheum       Date:  1998-12

5.  Specific activation of the nuclear receptors PPARgamma and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608.

Authors:  I Wiesenberg; M Chiesi; M Missbach; C Spanka; W Pignat; C Carlberg
Journal:  Mol Pharmacol       Date:  1998-06       Impact factor: 4.436

6.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Authors:  Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Jun Hashimoto; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Arthritis Rheum       Date:  2004-06

7.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Authors:  M E Weinblatt; J M Kremer; A D Bankhurst; K J Bulpitt; R M Fleischmann; R I Fox; C G Jackson; M Lange; D J Burge
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

8.  Identification of a novel rat microsomal vitamin D3 25-hydroxylase.

Authors:  Tomoaki Yamasaki; Shunsuke Izumi; Hiroshi Ide; Yoshihiko Ohyama
Journal:  J Biol Chem       Date:  2004-03-16       Impact factor: 5.157

9.  Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins.

Authors:  A J Silman; J Newman; A J MacGregor
Journal:  Arthritis Rheum       Date:  1996-05

10.  AT1 receptor characteristics of angiotensin analogue binding in human synovium.

Authors:  D A Walsh; T Suzuki; G A Knock; D R Blake; J M Polak; J Wharton
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

View more
  5 in total

1.  Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus.

Authors:  William E O'Gorman; Elena W Y Hsieh; Erica S Savig; Pier Federico Gherardini; Joseph D Hernandez; Leo Hansmann; Imelda M Balboni; Paul J Utz; Sean C Bendall; Wendy J Fantl; David B Lewis; Garry P Nolan; Mark M Davis
Journal:  J Allergy Clin Immunol       Date:  2015-05-30       Impact factor: 10.793

2.  A novel CD209 polymorphism is associated with rheumatoid arthritis patients in Taiwan.

Authors:  Hua-Chen Chan; Shu-Chen Wang; Chia-Hui Lin; Yuan-Zhao Lin; Ruei-Nian Li; Jeng-Hsien Yen
Journal:  J Clin Lab Anal       Date:  2021-04-01       Impact factor: 2.352

3.  RTD-1 therapeutically normalizes synovial gene signatures in rat autoimmune arthritis and suppresses proinflammatory mediators in RA synovial fibroblasts.

Authors:  Prasad Tongaonkar; Vasu Punj; Akshay Subramanian; Dat Q Tran; Katie K Trinh; Justin B Schaal; Teresina Laragione; André J Ouellette; Percio S Gulko; Michael E Selsted
Journal:  Physiol Genomics       Date:  2019-11-25       Impact factor: 4.297

4.  Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide.

Authors:  Justin B Schaal; Dat Q Tran; Akshay Subramanian; Reshma Patel; Teresina Laragione; Kevin D Roberts; Katie Trinh; Prasad Tongaonkar; Patti A Tran; Dmitriy Minond; Gregg B Fields; Paul Beringer; André J Ouellette; Percio S Gulko; Michael E Selsted
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

5.  Interleukin-17 contributes to Ross River virus-induced arthritis and myositis.

Authors:  Helen Mostafavi; Kothila Tharmarajah; Jelena Vider; Nicholas P West; Joseph R Freitas; Barbara Cameron; Paul S Foster; Linda P Hueston; Andrew R Lloyd; Suresh Mahalingam; Ali Zaid
Journal:  PLoS Pathog       Date:  2022-02-10       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.